MMRF Research: Immunoproteasome as a target for Myeloma therapy
From the Summer 2005 Newsletter of the Multiple Myeloma Research Foundation.
Robert Z. Orlowski, MD, PhD, University of North Carolina at Chapel Hill
Project Title: The Immunoproteasome as a target for multiple myeloma therapy
Abstract: Dr. Orlowski has identified a novel inhibitor of a specific myeloma proteasome called the immunoproteasome, which prevents the removal of unwanted and damaged proteins needed for myeloma cell death and remission. This agent killed myeloma cells but spared other cells in laboratory studies, while non-specific inhibitors like bortezomib caused death in all of them. These and other findings suggest that the immunoproteasome is a novel, distinct therapeutic target whose inhibition could help patients with myeloma while causing fewer side effects. Dr. Orlowski's new funding will examine the utility of this new class of drugs.
Robert Z. Orlowski, MD, PhD, University of North Carolina at Chapel Hill
Project Title: The Immunoproteasome as a target for multiple myeloma therapy
Abstract: Dr. Orlowski has identified a novel inhibitor of a specific myeloma proteasome called the immunoproteasome, which prevents the removal of unwanted and damaged proteins needed for myeloma cell death and remission. This agent killed myeloma cells but spared other cells in laboratory studies, while non-specific inhibitors like bortezomib caused death in all of them. These and other findings suggest that the immunoproteasome is a novel, distinct therapeutic target whose inhibition could help patients with myeloma while causing fewer side effects. Dr. Orlowski's new funding will examine the utility of this new class of drugs.
posted by gwg at 1:18 PM
0 Comments:
Post a Comment
<< Home